The Biologics News and Reports Portal

Show Cart

Target Pipelines

Results 41 - 50 of 66

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

450.00 €

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

300.00 €

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

150.00 €

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

400.00 €

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

200.00 €

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

1,140.00 €

1,900.00 €

(Discount: 40.00%)

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

700.00 €

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

200.00 €

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

500.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

Currencies

Shopping cart

Cart empty

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Target Pipelines

Nov 2017 Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update

Aug 2017 Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017

Apr 2017 Competitor Analysis: Kallikrein Inhibitors 2017

Mar 2017 Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Mar 2017 Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars

Dec 2016 Report Package: Hot targets for empowered antibody and cell therapy technologies

Nov 2016 CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Oct 2016 Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016

Aug 2016 B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing